丙种球蛋白注射剂联合阿司匹林肠溶片治疗川崎病的临床研究

发布时间：2018-04-26 15:20

  本文选题：丙种球蛋白注射剂 + 阿司匹林肠溶片　； 参考：《中国临床药理学杂志》2017年15期

【摘要】：目的观察丙种球蛋白注射剂联合阿司匹林肠溶片治疗川崎病的临床疗效及安全性。方法将88例川崎病患儿随机分为对照组44例和试验组44例。对照组予以阿司匹林50 mg·d~(-1),tid,口服;试验组在对照组治疗的基础上,予以人血丙种球蛋白1.5 m L,一次性肌内注射。2组患儿均治疗14 d。比较2组患儿的临床疗效、白细胞介素~(-1)7(IL~(-1)7)、IL-6、血管内皮生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)、MMP-9水平、内皮细胞数量,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为90.91%(40/44例)和77.27%(34/44例),差异有统计学意义(P0.05)。治疗后,试验组与对照组的IL~(-1)7分别为(17.32±3.83)和(42.67±4.38)ng·L~(-1),IL-6分别为(24.19±5.32)和(56.47±6.29)ng·L~(-1),VEGF分别为(109.73±18.17)和(147.32±17.69)ng·L~(-1),MMP-2分别为(0.47±0.15)和(0.84±0.17)ng·m L~(-1),MMP-9分别为(0.43±0.11)和(0.93±0.23)ng·m L~(-1),内皮细胞数量分别为(2.56±0.74)和(1.58±0.15)cell·μL~(-1),差异均有统计学意义(均P0.05)。试验组发生的药物不良反应主要有冠状动脉病变和胆囊积液,对照组发生的药物不良反应主要有冠状动脉病变、关节炎、胆囊积液,且试验组和对照组的药物不良反应发生率分别为6.82%和31.82%,差异有统计学意义(P0.05)。结论丙种球蛋白注射剂联合阿司匹林肠溶片治疗川崎病的临床疗效显著,且安全性较高。
[Abstract]:Objective to observe the efficacy and safety of gamma globulin injection combined with aspirin enteric-coated tablets in the treatment of Kawasaki disease. Methods 88 children with Kawasaki disease were randomly divided into control group (n = 44) and experimental group (n = 44). The control group was given aspirin 50 mg / d for oral administration, and the experimental group was given human gamma globulin 1.5 mL on the basis of treatment in the control group, and all the children in the control group were treated with intramuscular injection of 2.0 mg / L for 14 days. The clinical efficacy of the two groups was compared. The levels of IL-6, VEGF, MMP-2, MMP-9, the number of endothelial cells and the occurrence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 90.91% 40 / 44 cases and 77.27% / 44 cases respectively. The difference was statistically significant (P 0.05). 娌荤枟鍚，

本文编号：1806572